researchers Identify Key Molecule in Glioblastoma Resistance, Paving Way for Novel Therapies
A new study from Brown University Health and collaborating institutions has pinpointed a critical mechanism driving resistance to treatment in glioblastoma, the most aggressive form of brain cancer. the findings, published in Cell Reports, offer a potential new avenue for improving outcomes for patients facing this devastating diagnosis.
Glioblastoma is a particularly challenging cancer, classified by the World Health Institution (WHO) as the most common and aggressive malignant brain tumor in adults. Its rapid growth, difficulty in surgical removal, and high rate of relapse – even after aggressive treatment with surgery, radiotherapy, and chemotherapy – contribute to its poor prognosis.
The research reveals that the problem isn’t simply the tumor as a whole, but the remarkable diversity within the tumor itself. “Within the same glioblastoma, cells with very different behaviors coexist, something as if on the same team some players followed the rules and others did not,” explained a senior researcher involved in the study. This internal inconsistency hinders the effectiveness of chemotherapy, as treatments are frequently enough designed based on the “average” tumor profile, failing to account for these crucial internal differences.
“The customary approach looked at the tumor as a whole,” Chen stated. “We decided to look cell by cell, and that changed what we saw.”
This shift in perspective led to the identification of miR-181d, a small molecule known as a microRNA, which plays a central role in regulating the behavior of cancer cells. Researchers describe miR-181d as a “switch” that controls the production of a key protein.
The Role of MGMT and the Promise of Targeted Therapy
The protein regulated by miR-181d is called MGMT, a DNA repair system. When chemotherapy damages the genetic material of tumor cells, MGMT can “fix” that damage, enabling the cell to survive. consequently, the more MGMT a cell produces, the more resistant it becomes to treatment.
the study found that within a glioblastoma tumor, some cells produce high levels of MGMT, while others produce very little – creating a scenario where some cells are heavily protected while others are vulnerable. This disparity explains why, even after treatment, a population of cells remains capable of initiating tumor regrowth.
A key finding revealed that chemotherapy actually reduces miR-181d levels within the tumor. By suppressing this “switch,” internal disorder increases, and more cells begin to produce large amounts of MGMT, becoming resistant to treatment.
However, when researchers directly delivered miR-181d into the tumor, they observed a different effect. Cells began to behave more uniformly, producing more consistent levels of the repair protein. In essence, the tumor became less chaotic and more vulnerable to treatment.
Gene Therapy as a Potential Strategy
Based on these results, the research team proposed an experimental strategy centered on gene therapy, aimed at stabilizing the levels of miR-181d within the tumor. The goal isn’t to directly eliminate cancer cells, but to prevent them from developing resistance so readily.
Gatikrushna Singh, a neurosurgeon at the University of Minnesota and collaborator on the study, emphasized the potential clinical impact of this approach. “Clinically, it opens the door to strategies that could be game-changing for many glioblastoma patients,” he said.
Researchers at Brown University Health clarified that this work is currently in a preclinical stage. However, it has already facilitated the design of experimental therapies to test whether maintaining stable levels of miR-181d can enhance the effectiveness of chemotherapy.
This revelation doesn’t offer an immediate treatment solution, but it does present a new way of conceptualizing glioblastoma – not as a uniform enemy, but as a disordered system that could become more susceptible to treatment if the behavior of its cells can be coordinated. for a cancer notoriously difficult to treat, this shift in perspective could prove to be a significant step forward.
